CRISPR Therapeutics AG (CRSP) Research & Development (2016 - 2025)
Historic Research & Development for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $83.5 million.
- CRISPR Therapeutics AG's Research & Development rose 1643.2% to $83.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $284.8 million, marking a year-over-year decrease of 819.67%. This contributed to the annual value of $284.8 million for FY2025, which is 819.7% down from last year.
- As of Q4 2025, CRISPR Therapeutics AG's Research & Development stood at $83.5 million, which was up 1643.2% from $58.9 million recorded in Q3 2025.
- In the past 5 years, CRISPR Therapeutics AG's Research & Development ranged from a high of $123.2 million in Q2 2022 and a low of $58.9 million during Q3 2025
- For the 5-year period, CRISPR Therapeutics AG's Research & Development averaged around $89.2 million, with its median value being $83.5 million (2021).
- As far as peak fluctuations go, CRISPR Therapeutics AG's Research & Development soared by 18014.18% in 2021, and later crashed by 2830.82% in 2025.
- Over the past 5 years, CRISPR Therapeutics AG's Research & Development (Quarter) stood at $103.1 million in 2021, then grew by 0.45% to $103.6 million in 2022, then fell by 8.12% to $95.1 million in 2023, then fell by 24.6% to $71.7 million in 2024, then increased by 16.43% to $83.5 million in 2025.
- Its Research & Development stands at $83.5 million for Q4 2025, versus $58.9 million for Q3 2025 and $69.9 million for Q2 2025.